Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Zyvox Shows Higher Success Rate than Vancomycin: Pfizer
November 15, 2010
- Kyorin Licenses KRP-203 for IBD to Novartis
November 15, 2010
- Regorafenib's Efficacy Not Dependent on K-RAS Mutation: Bayer
November 15, 2010
- Santen Committed to Recapturing Top Share in Glaucoma Market
November 15, 2010
- Study Group for Developmentof New Adjuvants Created
November 15, 2010
- Takeda's Business to Hit Bottom in FY2013: President Hasegawa
November 15, 2010
- Astellas Acquires Diannexin Assets from Alavita
November 15, 2010
- JPA, JACDS Work to Improve Members' Business Practices
November 15, 2010
- Astellas Expects Additional Sales of ¥56 Bil. from OSI in FY2014
November 15, 2010
- Astellas to Integrate 3 Production Subsidiaries
November 15, 2010
- JMA Opposed to “Healthcare Tourism”
November 15, 2010
- Daiichi Sankyo to Independently Market Memantine
November 15, 2010
- Otsuka Changes Articles of Incorporation
November 15, 2010
- All-Patient Drug Use-Result Survey on Humira Completed
November 15, 2010
- Combined Half-Year Sales of Top-Eight Domestic Firms Up 1.8%
November 15, 2010
- Nippon Kayaku Ties Up with Celltrion to Develop Herceptin, Remicade Biosimilars
November 15, 2010
- Osteoporosis GL to Be Revised in 2011
November 15, 2010
- Astellas: Sales, Profits Down Due to Prograf Patent Expiration
November 15, 2010
- Savings by Generic Substitutionto to Taper Off: Mr Masuhara
November 15, 2010
- GSK Reduces Price of Cervarix by 30% in Canada
November 15, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…